商务合作
动脉网APP
可切换为仅中文
LEXINGTON, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced it has signed a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, has agreed to acquire, subject to the terms and conditions set forth in the agreement, all outstanding shares of Rapid Micro Biosystems at a price of $0.75 per share in an all-cash transaction..
马萨诸塞州列克星敦,2026年11月16日(环球电讯社)——Rapid Micro Biosystems, Inc.(纳斯达克股票代码:RPID)(“公司”)是一家创新的生命科学技术公司,提供关键任务自动化解决方案,以促进医疗保健产品的高效制造和快速、安全放行。该公司今日宣布,已签署一项最终协议,根据该协议的条款和条件,德国达姆施塔特的默克集团(Merck KGaA)同意以每股0.75美元的价格,通过全现金交易收购Rapid Micro Biosystems的所有流通股。
'Over the past 18 months, we have built a strong partnership with Merck KGaA, Darmstadt, Germany, centered on a shared commitment to innovation and helping customers modernize and automate their quality-control workflows,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems. “Rapid Micro has established the Growth Direct platform as the leading solution for automating microbial quality control, with most of the world's top pharmaceutical manufacturers as customers.
“在过去18个月中,我们与德国达姆施塔特的默克公司(Merck KGaA)建立了牢固的合作伙伴关系,其核心在于我们共同致力于创新,并帮助客户实现质量控制工作流程的现代化和自动化。”Rapid Micro Biosystems 总裁兼首席执行官 Robert Spignesi 表示。“Rapid Micro 已将 Growth Direct 平台确立为微生物质量控制自动化领域的领先解决方案,全球大多数顶尖制药制造商均已成为我们的客户。”
We are confident that joining the Life Science business of Merck KGaA, Darmstadt, Germany will significantly expand the Growth Direct platform’s reach and more fully serve our combined global customer base.'.
我们相信,加入德国达姆施塔特默克集团(Merck KGaA)的生命科学业务,将显著扩大Growth Direct平台的市场覆盖范围,并更全面地服务于我们共同的全球客户群。
“Quality control is essential to the reliable manufacture of medicines,” said Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany. “Our customers need reliable results faster, more efficient quality-control workflows and robust data integrity to support regulatory compliance.
“质量控制对于药品的可靠生产至关重要,”德国达姆施塔特默克集团(Merck KGaA)生命科学业务高级解决方案负责人保罗·卡利表示。“我们的客户需要更快地获得可靠结果,实现更高效的质量控制工作流程,并确保强大的数据完整性,以支持监管合规。”
Rapid Micro Biosystems will strengthen our ability to meet those needs, building on our existing offering and bringing greater automation to a critical step in pharmaceutical manufacturing.”.
“Rapid Micro Biosystems 将增强我们满足这些需求的能力,在我们现有产品的基础上,为制药生产中的关键步骤带来更高的自动化水平。”
Transaction Details
交易详情
The transaction is expected to close in December 2026, subject to the successful completion of the tender offer, including satisfaction of the minimum tender condition, and other customary closing conditions. Following completion of the transaction, Rapid Micro Biosystems will become part of the Life Science business of Merck KGaA, Darmstadt, Germany..
该交易预计将于2026年12月完成,前提是成功完成要约收购(包括满足最低要约收购条件)以及其他惯例交割条件。交易完成后,Rapid Micro Biosystems将成为德国达姆施塔特默克集团(Merck KGaA, Darmstadt, Germany)生命科学业务的一部分。
Advisors
顾问
Perella Weinberg Partners is serving as financial advisor to the Company and Goodwin Procter LLP is serving as legal counsel.
佩雷拉·温伯格合伙公司担任本公司的财务顾问,古德温·普罗克特律师事务所担任法律顾问。
About Rapid Micro Biosystems
关于Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe.
Rapid Micro Biosystems 是一家创新的生命科学技术公司,提供关键任务自动化解决方案,以促进生物制品、疫苗、细胞和基因疗法以及无菌注射剂等医疗保健产品的高效生产和快速、安全放行。该公司的旗舰产品 Growth Direct 系统自动化并现代化了全球最大且最复杂的制药生产运营中使用的传统、手动微生物质量控制(“MQC”)检测工作流程。
The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products.
Growth Direct 系统将质量控制实验室延伸至生产现场,通过释放 MQC 自动化的潜力,提供更快的检测结果、更高的准确性、提升的运营效率、更好的数据完整性法规合规性以及更迅速的决策支持,帮助客户确保重要医疗保健产品的安全且稳定的供应。
The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit .
公司总部位于马萨诸塞州列克星敦,在美国马萨诸塞州洛厄尔设有制造基地,并在瑞士、德国和荷兰设有全球分支机构。欲了解更多信息,请访问。
www.rapidmicrobio.com
www.rapidmicrobio.com
or follow the Company on X (formerly known as Twitter) at
或在 X(前身为 Twitter)上关注本公司,账号为
@rapidmicrobio
@快速微生物
or on
或在
领英
.
。
Rapid Micro Biosystems intends to use the Investor Relations page of its website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor its website in addition to following press releases, filings with the Securities and Exchange Commission (“SEC”), public conference calls, presentations and webcasts. .
Rapid Micro Biosystems 计划利用其网站上的投资者关系页面作为披露重大非公开信息的手段,并以此履行其在《公平披露条例》(Regulation FD)下的披露义务。因此,投资者除了关注新闻稿、向美国证券交易委员会(“SEC”)提交的文件、公开电话会议、演示和网络直播外,还应定期查看其网站。
Additional Information and Where to Find It
附加信息及查询方式
The tender offer described in this communication has not yet commenced, and this communication is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, Merck KGaA, Darmstadt, Germany and EMD Holdings NewCo II, Inc. (“Purchaser”) will file a tender offer statement on Schedule TO with the U.S.
本通讯所述的要约收购尚未开始,且本通讯不构成购买要约,也不构成出售证券的要约邀请。在要约收购开始时,德国达姆施塔特的默克公司(Merck KGaA)和 EMD Holdings NewCo II, Inc.(“买方”)将向美国提交基于 TO 表的要约收购声明。
Securities and Exchange Commission (the “SEC”), and Rapid Micro Biosystems (“Rapid”) will file a solicitation/recommendation statement on Schedule 14D-9 with the SEC. INVESTORS AND SECURITY HOLDERS ARE STRONGLY ADVISED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED TENDER OFFER DOCUMENTS) THAT WILL BE FILED BY MERCK KGAA, DARMSTADT, GERMANY AND PURCHASER WITH THE SEC AND THE RELATED SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 THAT WILL BE FILED BY RAPID WITH THE SEC, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
美国证券交易委员会(“SEC”)以及 Rapid Micro Biosystems(“Rapid”)将向 SEC 提交 Schedule 14D-9 格式的征求/推荐声明。强烈建议投资者和证券持有人在上述文件可供查阅时,仔细阅读由德国达姆施塔特的默克集团(Merck KGaA, Darmstadt, Germany)及购买方将向 SEC 提交的要约收购声明(包括购买要约、传送函及相关要约收购文件),以及由 Rapid 将向 SEC 提交的 Schedule 14D-9 格式的相关征求/推荐声明,因为这些文件将包含重要信息。
These materials (once they become available) will be made available to Rapid shareholders at no cost by the information agent for the tender offer. Once filed, these documents will be available at no charge on the SEC’s website at www.sec.gov. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may be obtained free of charge from Merck KGaA, Darmstadt, Germany under the “Investors” section of Merck KGaA, Darmstadt, Germany’s website at .
这些材料(一旦发布)将由要约收购的信息代理免费提供给Rapid的股东。提交后,这些文件将在美国证券交易委员会(SEC)网站www.sec.gov上免费提供。此外,可以从德国达姆施塔特的默克公司(Merck KGaA)免费获取购买要约、递交函以及其他某些相关的要约收购文件(一旦发布),具体可在德国达姆施塔特默克公司网站的“投资者”栏目下找到。
https://www.emdgroup.com/en
https://www.emdgroup.com/zh
. A copy of the solicitation/recommendation statement (once it becomes available) also may be obtained free of charge from Rapid under the “Investor Relations” section of Rapid’s website at
. 征购/推荐声明的副本(一旦发布)也可在 Rapid 网站“投资者关系”栏目下免费获取,网址为
https://www.rapidmicrobio.com/
https://www.rapidmicrobio.com/
.
。
Forward-Looking Statements
前瞻性陈述
This press release includes “forward-looking statements” regarding the potential acquisition of Rapid. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other words and terms of similar meaning..
本新闻稿包含有关可能收购 Rapid 的“前瞻性陈述”。除历史事实陈述外,所有陈述均可能构成前瞻性陈述。这些前瞻性陈述可能伴有“展望”、“目标”、“预期”、“假设”、“相信”、“考虑”、“继续”、“可能”、“由于”、“估计”、“期望”、“宗旨”、“打算”、“可以”、“目的”、“计划”、“预测”、“潜在”、“定位”、“寻求”、“应当”、“靶向”、“将”、“将会”等词语以及具有类似含义的其他字词和术语。
Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties..
提醒读者,任何此类前瞻性陈述均不构成对未来表现的保证,且涉及风险和不确定性,因此请勿过度依赖这些前瞻性陈述。由于存在多种风险和不确定性,实际结果可能与当前预期存在重大差异。
Risks and uncertainties include, but are not limited to: the risk that the closing conditions for the proposed acquisition will not be satisfied, including the risk that the necessary regulatory approvals may not be obtained or may be obtained subject to conditions that are not anticipated; uncertainty as to the percentage of Rapid stockholders that will support the proposed acquisition and tender their shares in the offer; the risk of stockholder litigation relating to the proposed acquisition, including resulting expense or delay; the possibility that the proposed acquisition will not be completed in the expected timeframe or at all; potential adverse effects to the businesses of Merck KGaA, Darmstadt, Germany or Rapid during the pendency of the proposed acquisition, such as employee departures or distraction of management from business operations; the potential that the expected benefits and opportunities of the proposed acquisition, if completed, may not be realized or may take longer to realize than expected; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; potential adverse reactions or changes to business relationships resulting from the proposed acquisition, including the effect of the acquisition on the ability to maintain key vendor, supplier or partner relationships; and risks related to the integration of Rapid into Merck KGaA, Darmstadt, Germany subsequent to the closing of the proposed acquisition and the timing of such integration..
风险和不确定性包括但不限于:拟议收购的交割条件可能无法满足的风险,包括可能无法获得必要的监管批准,或获得的批准附带不可预见的条件;不确定有多少比例的 Rapid 股东将支持拟议收购并在要约中提交其股份;与拟议收购相关的股东诉讼风险,包括由此产生的费用或延误;拟议收购可能无法在预期时间内完成或根本无法完成的可能性;在拟议收购悬而未决期间,对德国达姆施塔特默克公司(Merck KGaA, Darmstadt, Germany)或 Rapid 的业务可能产生的潜在不利影响,例如员工离职或管理层因业务运营分心;如果拟议收购完成,其预期的利益和机会可能无法实现,或实现时间长于预期的可能性;任何可能导致终止合并协议的事件、变化或其他情况的发生;因拟议收购而导致的潜在不利反应或业务关系变化,包括收购对维持关键供应商、供货商或合作伙伴关系能力的影响;以及在拟议收购交割后将 Rapid 整合进德国达姆施塔特默克公司的相关风险及该等整合的时间安排。
A further list and descriptions of these risks, uncertainties and other factors can be found in Rapid Micro Biosystems’ Annual Report on Form 10-K for the fiscal year ended 31 December 2025, including in the sections captioned “Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Rapid Micro Biosystems’ subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC.
这些风险、不确定性和其他因素的进一步列表及描述,可参见 Rapid Micro Biosystems 截至 2025 年 12 月 31 日财政年度的 Form 10-K 年度报告,包括其中题为“前瞻性陈述”和“第 1A 项. 风险因素”的章节,以及 Rapid Micro Biosystems 随后提交的 Form 10-Q 季度报告和其他向美国证券交易委员会(SEC)提交的文件。
Copies of these filings are available online at www.sec.gov or https://investors.rapidmicrobio.com/. Rapid Micro Biosystems is not under any obligation, and expressly disclaims any obligation, to update or otherwise revise any forward-looking statements, whether as a result of new information, future events, or otherwise..
这些备案文件的副本可在 www.sec.gov 或 https://investors.rapidmicrobio.com/ 在线获取。Rapid Micro Biosystems 没有任何义务,并明确否认有任何义务,因新信息、未来事件或其他原因而更新或以其他方式修订任何前瞻性陈述。